for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PerkinElmer, Inc.

PKI

Latest Trade

135.68USD

Change

2.68(+2.02%)

Volume

325,734

Today's Range

131.94

 - 

135.69

52 Week Range

62.91

 - 

142.65

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

PerkinElmer Posts Q3 Adjusted Earnings Per Share $2.09 From Continuing Operations

Oct 28 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2020.Q3 ADJUSTED EARNINGS PER SHARE $2.09 FROM CONTINUING OPERATIONS.Q3 GAAP EARNINGS PER SHARE $1.57 FROM CONTINUING OPERATIONS.SEES Q4 2020 ADJUSTED NON-GAAP EARNINGS PER SHARE $2.60 TO $3.00.SEES Q4 2020 GAAP EARNINGS PER SHARE $2.27 TO $2.67 FROM CONTINUING OPERATIONS.SEES Q4 2020 REVENUE $1.12 BILLION TO $1.23 BILLION.Q3 EARNINGS PER SHARE ESTIMATE $1.50 -- REFINITIV IBES DATA.QTRLY REVENUE OF $964.0 MILLION.Q4 EARNINGS PER SHARE VIEW $1.82, REVENUE VIEW $939.7 MILLION -- REFINITIV IBES DATA.

Perkinelmer Sets Regular Quarterly Dividend Of $0.07 Per Share

Oct 22 (Reuters) - PerkinElmer Inc <PKI.N>::SETS REGULAR QUARTERLY DIVIDEND OF $0.07PER SHARE.

PerkinElmer Sees Q3 Reported Revenue Growth Of ~35%

Oct 12 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER UPDATES THIRD QUARTER OUTLOOK; TO HOLD EARNINGS CALL ON WEDNESDAY, OCTOBER 28, 2020.ANTICIPATES REPORTED AND ORGANIC REVENUE GROWTH OF APPROXIMATELY 35% AND 33%, RESPECTIVELY, FOR Q3 ENDED OCTOBER 4, 2020.COVID-19 RELATED SOLUTIONS CONTRIBUTED ABOUT $280 MILLION OF REVENUE IN Q3.Q3 REVENUE VIEW $829.0 MILLION -- REFINITIV IBES DATA.

Perkinelmer Launches DA 7350 Instrument & Cloud-Based Software For Quality Control In Food Production

Sept 15 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER - LAUNCHES DA 7350 INSTRUMENT & CLOUD-BASED SOFTWARE FOR QUALITY CONTROL IN FOOD PRODUCTION.

Perkinelmer Sees Q3 2020 Revenue $760 Million To $860 Million

July 28 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2020.Q2 ADJUSTED EARNINGS PER SHARE $1.57 FROM CONTINUING OPERATIONS.Q2 GAAP EARNINGS PER SHARE $1.23 FROM CONTINUING OPERATIONS.SEES Q3 2020 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.18 TO $1.53.SEES Q3 2020 GAAP EARNINGS PER SHARE $0.85 TO $1.20 FROM CONTINUING OPERATIONS.SEES Q3 2020 REVENUE $760 MILLION TO $860 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.88 -- REFINITIV IBES DATA.Q2 REVENUE $811.7 MILLION VERSUS $722.5 MILLION.Q3 EARNINGS PER SHARE VIEW $1.12, REVENUE VIEW $764.4 MILLION -- REFINITIV IBES DATA.

Perkinelmer Releases New Dried Blood Spot Based Covid-19 Serology Test

July 21 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER RELEASES NEW DRIED BLOOD SPOT BASED COVID-19 SEROLOGY TEST.PERKINELMER INC - FINGER-PRICK SAMPLE COLLECTION DEVICE ALLOWS FOR BOTH DECENTRALIZED SAMPLE COLLECTION AND HIGH-THROUGHPUT TESTING.PERKINELMER INC - PRODUCT IS BEING MARKETED AS A CE-IVD TEST.PERKINELMER INC - PLANS TO APPLY FOR EUA WITH U.S. FOOD AND DRUG ADMINISTRATION FOR THE TEST.

Perkinelmer Says Covid-19 Related Solutions Contributed Approx $190 Mln Of Revenue In Q2

July 13 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER UPDATES SECOND QUARTER OUTLOOK; TO HOLD EARNINGS CALL ON TUESDAY, JULY 28, 2020.COVID-19 RELATED SOLUTIONS CONTRIBUTED APPROXIMATELY $190 MILLION OF REVENUE IN Q2.ANTICIPATES GROWTH IN BOTH REPORTED REVENUE AND ORGANIC REVENUE OF APPROXIMATELY 12% FOR Q2 ENDED JULY 5, 2020.Q2 REVENUE VIEW $668.9 MILLION -- REFINITIV IBES DATA.

PerkinElmer Says Got Subpoenas From Government Regarding Investigations Into Third Parties

May 18 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER - GOT SUBPOENAS FROM GOVERNMENT REGARDING INVESTIGATIONS INTO THIRD PARTIES.

Perkinelmer Reports Q1 Adj EPS Of $0.67 From Continuing Operations

May 5 (Reuters) - PerkinElmer Inc <PKI.N>::PERKINELMER ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2020.Q1 ADJUSTED EARNINGS PER SHARE $0.67 FROM CONTINUING OPERATIONS.Q1 GAAP EARNINGS PER SHARE $0.30 FROM CONTINUING OPERATIONS.SEES Q2 2020 ADJUSTED NON-GAAP EARNINGS PER SHARE AT LEAST $0.65.SEES Q2 2020 GAAP EARNINGS PER SHARE AT LEAST $0.33 FROM CONTINUING OPERATIONS.SEES Q2 2020 REVENUE $610 MILLION TO $720 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.55 -- REFINITIV IBES DATA.WITHDRAWING PREVIOUSLY DISSEMINATED FY20 GUIDANCE DUE TO COVID-RELATED UNCERTAINTIES.Q1 REVENUE $652.4 MILLION VERSUS $648.7 MILLION.Q1 EARNINGS PER SHARE VIEW $0.54, REVENUE VIEW $651.0 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $0.70, REVENUE VIEW $667.7 MILLION -- REFINITIV IBES DATA.

FDA Provides Emergency Use Authorization To Perkinelmer For Serological Test To Identify Covid-19 Antibodies

May 5 (Reuters) - PerkinElmer Inc <PKI.N>::FDA PROVIDES EMERGENCY USE AUTHORIZATION TO PERKINELMER FOR SEROLOGICAL TEST TO IDENTIFY COVID-19 ANTIBODIES.PERKINELMER INC - EUROIMMUN HAS CAPACITY TO MANUFACTURE MILLIONS OF ASSAYS PER MONTH..PERKINELMER INC - SINCE MARCH, EUROIMMUN HAS ALREADY STARTED SHIPPING ITS ANTI-SARS-COV-2 ELISA.PERKINELMER INC - EUROIMMUN INTENDS TO FURTHER BUILD PRODUCTION CAPACITY TO MEET HEIGHTENED DEMAND..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up